3billion
Overview
3billion offers AI-powered genetic testing for rare disease diagnosis, providing services for clinicians and patients. The platform aims to assist in diagnosing patients who have spent years without a clear explanation for their symptoms, suggesting rare diseases as a potential answer.
- What it does: 3billion provides genetic testing services including 3B-GENOME and 3B-EXOME, with results available within four weeks. It also offers GEBRA™ for converting VCF files to final reports. The technology incorporates AI tools such as EVIDENCE, which classifies whole exome sequencing (WES) variants, 3Cnet for predicting pathogenicity of variants lacking evidence, and 3ASC for ranking candidate variants by symptom similarity.
- Who it is for: The services are intended for clinicians treating patients with suspected rare diseases.
- How it fits a clinical or practice workflow: Clinicians can order genetic tests, receive sample kits, and obtain clear test reports. The platform also includes clinical consultation and continuous reanalysis of undiagnosed cases until a diagnosis is found. Clinicians can ask about results, request VUS reviews, or share new symptoms for reinterpretation.
- Notable capabilities:
- EVIDENCE: Classifies approximately 100,000 WES variants in an average of 5 minutes, adhering to ACMG criteria with 98.4% sensitivity and 99.99% specificity.
- 3Cnet: AI predicts pathogenicity for variants lacking evidence, showing 2.2 times higher sensitivity and improving VUS reclassification.
- 3ASC: Ranks candidate variants by symptom similarity, identifying the causative variant in the top 5 in 96% of cases.
- Reanalysis: Undiagnosed cases are continuously reanalyzed.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered genetic testing
- Variant analysis automation
- Enhanced accuracy in genetic testing
- Faster results (within 4 weeks for 3B-GENOME & 3B-EXOME)
- EVIDENCE: Classifies ~100,000 WES variants in 5 minutes (98.4% sensitivity, 99.99% specificity)
- 3Cnet: AI predicts pathogenicity for variants lacking evidence (2.2x higher sensitivity)
- 3ASC: Ranks candidate variants by symptom similarity (causative variant in top 5 in 96% of cases)
- Reanalysis of undiagnosed cases
- Clinical consultation
- Easy ordering with sample kit included
Use Cases
- Rare disease diagnosis
- Genetic variant interpretation
- Reanalysis of undiagnosed genetic cases
- Drug discovery
What Physicians Need to Know
Leverage the reanalysis service for undiagnosed patients, as the platform continuously re-evaluates data with new evidence. Utilize the clinical genetics team for consultations, VUS reviews, and reinterpretation based on new symptoms.
The platform supports clinicians globally, with testing available in over 70 countries and used by over 2,200 clinicians. It also partners with global pharma for precision prescribing.
Details
| Category | Clinical Decision Support & Reference, Lab & Diagnostics |
| Pricing | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Unknown |
| Integrations | |
| EHR | Not specified |
| Specialties | Laboratory Medicine, Neurology, Pediatrics |
Ratings & Reviews
No reviews yet. Be the first to review this tool!





